Richard Chesworth - Aug 27, 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Scientific Officer
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol: KYMR
Transactions as of: Aug 27, 2021
Transactions value $: -$1,355,284
Form type: 4
Date filed: 8/27/2021, 04:55 PM
Previous filing: Aug 19, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Options Exercise	$676K	+33.8K		$20.00	33.8K	Aug 27, 2021	Direct
transaction	KYMR	Common Stock	Sale	-$2.03M	-33.8K	-100%	$60.12	0	Aug 27, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-33.8K	-11.37%	$0.00	263K	Aug 27, 2021	Common Stock	33.8K	$20.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.99 to $60.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3	Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter.